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Arterial allografts, formerly called homografts, came into limited use in the 1940s and 1950s as arterial substitutes. Fresh 
allografts underwent rapid rejection. Preserved allografts had a longer but still limited clinical life. Allografts demonstrated 
that arterial replacement was a valid concept and le to the development of synthetic substitutes. Recent renewed interest 
is based on the need for graft replacements in re-do procedures and i  an infected field. Even the best methods f graft 
procurement and preservation do not preserve normal endothelial and smooth muscle cell functions nor eliminate 
antigenicity. The biologic and economic costs of immune suppression to obtain a successful allograft for an ischaemic limb 
are presently unjustifiable. Transplantation between species (xenotransplantation) may be t inable via selective inhibition 
of the complement system avoiding full immunosuppression now required for organ transplantation. At present allografts 
may be an acceptable choice for the patient with (1) a critical need for revascularisation and with a life expectancy not 
exceeding that of the graft, (2) in urgent vascular trauma, and(3) where immunosuppression is contraindicated as in an 
infected surgical field. Except in most unusual circumstances allografts should n t be used for (1) relief of claudication, (2) 
in the above mid-calf location nd (3) anatomic locations where synthetic grafts are superior. 
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Introduction 
The first recorded use of arterial and venous homo- 
grafts was apparently by German surgeons during 
World War I. Other casualties provided the grafts 
which invariably thrombosed. 1 Gross et al. in 1948, 
reported the use of allegedly viable human arterial 
homografts taken from trauma victims. 2'3 Contrary to 
belief based on fibroblast cell cultures these grafts did 
not retain viability, and at best, may have merely 
provided a scaffold for ingrowth of host cells, an 
observation of Guthrie 30 years earlier. 4 In a 1947 
review of 12 "viable homografts" inserted in dogs, 
nine "broke down" and intimal sclerosis and fibrosis 
occurred in three. Haemorrhage was the cause of 
death in 75%. Because of their presumed lesser 
immune response, nonviable (preserved) grafts came 
to be preferred. 5-7 
Arterial Homografts (AIIografts) 
The need for graft replacement of arteriosclerotic 
vessels was much greater than for correction of 
congenital and acquired cardiovascular defects. Ini- 
tially the problem was seen as merely mechanical, 
replacing a diseased peripheral artery with a normal 
one for its blood conducting properties. Fresh allog- 
rafts underwent rapid rejection and dissolution. Pre- 
served grafts were thought to be less so and arterial 
banks became standard in many vascular centres. 
Harvesting, sterilising, and preserving rafts utilised 
formalin, alcohol, glycerine, ethylene oxide, betapro- 
priolactone, high voltage cathode ray irradiation, and 
freeze drying. Each had its shortcomings. 8-17 Abun- 
dant historical evidence that complex tissues cannot 
be exchanged between umbers of the same species 
was ignored. In time preserved grafts displayed their 
shortcomings as well. Nevertheless, driven by increas- 
ing clinical need and lack of a satisfactory substitute, 
vascular surgeons were quick to use the preserved 
allograft in the 1950s. In 1952, Dubost et al. inserted a 
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homograft after resection of an abdominal aortic 
aneurysm followed almost simultaneously with loss 
of the fibrillar structure of the elastic lamina of the 
aortic graft created a localised area of marked reduc- 
tion of tensile strength. These two events, conversion 
of the fibrillar structure of the elastic lamina of the 
wall to an amorphous ubstance and atheromatous 
invasion, are the probable starting point of aneurysm 
formation. 28
Venous Homografts (AIIografts) 
The belief that venous allografts would function 
satisfactorily was based on several largely erroneous 
assumptions: 
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Fig. 1. Cumulative patenc)5 closure, and death rates in 132 cases of 
aortoiliac allografts. From: Szilagyi DE, Rodriguez FJ, Smith RF, 
Elliott JP. Late fate of arterial llografts: observations 6 to 15 years 
after implantation. Arch Surg 1970; 101: 721-733. With permission. 
(1) veins were less antigenic than arteries because of 
their lesser amount of smooth muscle ~9"3° 
(2) freezing, prior to transplantation, rendered veins 
even less antigenic 3~ and 
(3) because of a thinner wall the vein allograft may 
derive more nutrients from intraluminal flow than 
arteries, which, being more dependent on vasa 
vasorum, are more likely to undergo ischaemic 
degeneration leading to fibrosis and aneurysm 
formation. 
Transplantation antigens were demonstrated on 
endothelial cells as early as 1971, 32 yet their use was 
continued in the arterial position with 45% 4 year 
patency rates. 32-35 Based on 46 patients, Tice and 
Zerbino stated in 1972 that "at present vein allografts 
are safe and satisfactory substitutes when satisfactory 
autogenous vein is not available;" they also main- 
tained that problems with infection, aneurysmal dila- 
tion, acute necrosis or atherosclerosis were not 
seen. 34"35 Immunologic factors were considered the 
major cause of failure of canine allografts (64%) 
compared to autografts (12.5%), and, whatever the 
mechanism, Perloff demonstrated that allografts defi- 
nitely sensitised their canine and rat hosts. 36 In 1975, 
Williams et aI. demonstrated in a canine model that the 
endothelium was virtually destroyed by day 11 after 
implantation, medial necrosis was apparent by day 20 
and was universal in all allografts by day 40. Smooth 
muscle was replaced by dense connective tissue, 
monocytes infiltrated the endothelium penetrating 
below the internal elastic lamina as in early ather- 
ogenesis, and the eventual result was a tube devoid of 
smooth muscle and consisting largely of collagen. 37 
Synthetic Grafts 
The arterial allograft experience, although of very 
limited success, and plagued by cumbersome methods 
of procurement and preservation, was a major impe- 
tus in the development of vascular surgery because it
demonstrated that substitutes could work in the 
arterial system. Essentially biologically inert synthetic 
materials into which connective tissue could grow 
from the host and which provided support for a non- 
thrombogenic surface gave rise to reconstructive 
vascular surgery. The best of available synthetic tubes 
perform poorly in regions of low flow and high 
resistance, in re-do operations increasingly distant 
from a main conduit vessel, and in areas of infection. 
All too often autogenous saphenous vein is lacking or 
of poor quality. The increasing extension of surgical 
indications into more distal and smaller arterial beds, 
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Fig. 2. Acute endothelial destruction in aortic allografts: (A) 5 days after gaffing. The endothelial cells and their nuclei are rounded instead 
of oval or oblong. The cell insinuating itself between the two endothelial cells is a large mononuclear cell. The vein gr ft demonstrates 
rounded endothelial cells and penetration of a large mononuclear cell between two endothelial cells. (Electron micrograph; original 
magnification × 3100). From Williams GM et al. Rejection and repair of endothelium in major vessel transplants. Surgery 1975;78: 694-706. 
With permission. (B) 11 days after grafting. Theendothelium in this area is completely destroyed. Platelets in various degrees of 
degeneration and amorphous material comprise the vascular surface of the graft. Smooth muscle cells are still normal in appearance. 
(Original magnification × 3100). From Williams GM et aI. Rejection and repair of endothelium in major vessel transplants. Surgery; 1975; 
78: 694-706. With permission. 
the greater complexity of the vascular econstruction 
problem, the increase in secondary re-do operations 
and the presence of infection make a revisit to the 
venous (and arterial) allograft quite understandable. 
Return of the AIIograft 
A number of anecdotal reports recording functioning 
allografts 10 and more years after insertion, usually of 
aortoiliac segments, demonstrated that not all allog- 
rafts were failures. 27 The larger smooth muscle com- 
ponent of muscular arteries such as the femoral and 
popliteal, compared to the greater elastic content of 
the iliac and aortic segments rendered the former 
more antigenic and accounted for their poorer func- 
tion. The further presumption was that elastic ele- 
ments were less immunogenic than muscular ele- 
ments. These observations as to wall composition and 
greater durability of elastic implants are correct. The 
assumptions concerning degrees of antigenicity are 
just that for there seem to be formal confirming data. 
The antigenicity of muscular and elastic arteries must 
be greatly reduced by the cycotoxicity of sterilisation 
and preservation. It is surprising that so little analysis 
has been done on the immune aspects of the artery 
and the possibility of immunosuppressive tr atment 
after implantation given the potential usefulness of 
the technology. 
Cryopreservation 
Although many laboratory and clinical studies over 
many years, have examined the results of cryopre- 
servation, irradiation and immunosuppressive ther- 
apN and most were modestly optimistic, the clinical 
studies were uncontrolled, non-randomised, and of 
short follow-up. Boren and Moore concluded that 
cryopreservation f canine artery segments in liquid 
nitrogen and 15% dimethyl sulphoxide (DSMO), an 
oxygen radical scavenger, was an excellent method for 
preserving and storing fresh allograft arteries for use 
as a small vessel replacement. 3s Careful analysis yields 
the realisation that, in realitN preserved grafts are 
superior to fresh grafts, an observation already 
accepted in clinical practice. Abbott's group reported 
that short-term freezing of canine jugular venous 
allografts preserved the important functional elastic 
properties of veins independent ofDSMO. 39 Giordano 
combined irradiation with freezing of canine external 
jugular veins placed in the femoral position and 
compared their function with autografts at 6 months. 
Eighty-three percent of he autografts and 72% of the 
prepared allografts were patent. They suggested that 
the recipient's immunologic reaction to the graft did 
not affect patency and further suggested that irradia- 
tion may have significantly reduced the immunologic 
potential of the graft. These were speculations unsup- 
ported by objective, controlled ata and weaken their 
concluding statement that systemic suppression of the 
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recipient's immune response may not be necessary if
frozen, irradiated allografts are used for arterial or 
venous replacement. 4° Numerous other studies with 
variations in technique reported modestly favourable 
results but they all suffered from non-randomisation, 
small series, limited follow-up periods and sparse 
histologic observations. 4°~2 A literature review of 
venous allografts revealed a 1 year patency rate of 
approximately 50%. 43 
Despite many attractive aspects of studies of experi- 
mental saphenous allograft clinical usage had a high 
failure rate. Evidence continued to identify failure as 
initiated by immunologically induced thrombosis as a 
consequence of damaged endothelium. Better patency 
was achieved with frozen than with fresh allografts. 
Freezing was a deliberate attempt o destroy cellular 
elements and thereby reduce antigenicity as well as to 
facilitate storage. 44 
Attempts to improve allograft performance include 
histocompatibility matching of the vein donor and 
allograft recipient, graft recipient immunosuppres- 
sion, blood group matching and pretreatment of grafts 
33 45-47 with immunosuppressive agents. " Cryopreser- 
vation, in contrast to simple freezing and frozen 
storage techniques, is intended to preserve some cell 
functions by careful control of rate of cooling and 
prevention of ice nucleation. It has been labelled 
cryoprotection based on an observation that glycerol 
exerted a protective effect on frozen and thawed 
spermatozoa, 48 and that freeze damage to living cells 
could be prevented by DMSO, especially when com- 
bined with chondroitin sulphate. 49-53 Barner et al. 
appear to have applied it to vascular surgery in 1966, 50 
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Fig. 3. Patency rate and level of distal anastomosis (Kaplan & Meyer 
life table analysis) From: Leersnidjer DE, Willcox E van Marck E. 
Vanmaele R. Venous homograffs in infra-inguinal procedures: an 
eight year experience. ] Cardiovasc Surg 1992; 33: 633-640. With 
permission. 
but multiple technical variations made it difficult if 
not impossible to assess its value. 
Cryopreservation, although a marked improvement 
over simple freezing, has several limitations and both 
laboratory and clinical studies are confusing and 
occasionally conflicting. Connective tissue and smooth 
muscle contractility are reduced 45-50% of those in 
fresh veins. Nerve terminal function is compromised. 
Endothelial cell and smooth muscle cell functions, 
once thought to remain normal, are not. It has been 
claimed that cryopreserved human and canine veins 
retain their basic morphologic structure and fibrino- 
lytic activity. 54"5s Brockbank claimed that "cryopre- 
servation in medium containing DMSO between -135 
and -194°C. offers the prospect of virtually infinite 
storage of isolated blood vessels. Despite reduced 
contractile forces and overall endothelial functions, 
the main biochemical properties, uptake mechanisms 
and affinities for agonists and antagonists have been 
shown to be preserved after thawing" .53 
By contrast, Miller and associates tate that canine 
saphenous vein cryopreserved allografts, utilising 
chondroitin sulphate, did not respond to any of the 
agonists tested, that histologic examination indicated 
some smooth muscle cells but not in sufficient 
DMSO only control 
Fresh untreated 
CS entire process 
CS except freeze 
] ~ 
~NS 
vN 
No cryoprotectants ~ * 
I r r I _ 
1 2 3 4 5 
Endothelial cells (× 1000)/cm 
Fig. 4. Chondroitin sulphate promotes endothelial cell survival in 
cryopreserved veins. Limiting dilution assay results comparing 
survival of clonogenic endothelial cells in canine saphenous veins 
cryopreserved with 10% dimethyl sulpboxide (DMSO) alone or in 
combination with 2.5% chondroitin sulphate (CS). Results of 
experiments in which chondroitin sulphate was employed in all 
stages of vein processing except during cryopreservation n the 
presence ofdimethyl sulphoxide, zero cryoprotectant controls, and 
untreated controls are also presented. NS = no significant differ- 
ence. • = statistical significance using a paired t-test at the p < 0.05 
confidence l vel. From: Brockbank KGM. Effects of Cryopreserva- 
tion upon Venous Functions. In: Brockbank KGM, ed. Principles of 
autologous, allogeneic, and cryopreserved venous transplantation. Austin, 
TX: RG Landes, 1995. With permission. 
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quantity to sustain contraction. Evidence of rejection 
was observed in all allografts. Cyclosporine, for 
immune suppression and aspirin for platelet control, 
were used selectively. Both freshly harvested and 
cryopreserved allografts showed signs of rejection 
even with cyclosporin immunosuppression. Even 
with evidence of rejection grafts remained patent, but 
patency was not examined beyond 30 days of implan- 
tation, s6 In summary, despite extensive xperimental 
study and scattered encouraging clinical reports, 
cryopreserved vein grafts in human arterial recon- 
structions have had only limited success. Refinements 
in graft harvesting and processing, multiple cryopro- 
tectants, and partial immunosuppression have not 
entirely solved the problem of vascular allografts. 
Immunologic response of the host to the graft appears 
44 47 56-5v  to be a continuing and major problem. ' ' 
Immunosuppression 
The successful use of both venous and arterial 
allografts in both the venous and arterial circulations 
requires that they be considered and treated as true 
organ transplants as has been the case for kidne~ liver 
and other organs for decades. To continue to attempt 
to achieve success with partial solutions, valuable as 
they have been in defining the scope of the problem, is 
to risk waste of limited research resources and time. 
Under special and limited conditions the vascular 
allograft can be used successfully without conven- 
tional transplantation immune suppression therapy. 
These special situations include, but probably are not 
limited to: (1) the individual with a severely ischaemic 
leg and a life expectancy not exceeding the functional 
life of the allograft, (2) emergent replacement of a 
short segment of a major vessel lost to trauma or 
sacrificed to malignancy, (3) when immunosuppres- 
sion is contra-indicated as in an infected surgical field, 
and (4) in patients whose immune system is already 
compromised. 6°'61 For more extensive use and where 
there is a true need, as in small diameter vascular 
replacements, fulMmmunosuppression is needed. 
This position is supported by two observations: 
(1)the failure of cryopreservation, and all other 
methods eeking to preserve viability of the graft, 
to eradicate the antigenicity of the implanted 
vessel, and 
(2) the successful long term patency rates anecdotally 
reported among patients receiving full immuno- 
suppression therapy for other organ transplanta- 
tion, and in whom a vascular allograft is later 
implanted. 
To expand on the first point: cell surface structures 
involved in allograft rejection are identified variously 
as transplantation a tigens, endothelial cell surface 
antigens, histocompatibility antigens, and human 
leukocyte antigens (HLAs). These are encoded in a 
genomic location known as the major histocompatibil- 
ity complex (MLC). Arterial and venous allografts 
obtained at random from unrelated onors may very 
ikely differ substantially from the recipient's HLA 
antigens and thus can engender ejection. Class I 
antigens (HLA A, B and C loci) recognise "killer" T 
lymphocytes. These T cells mediate the damage to the 
allografts and constitute the effector limb of the 
cellular immune response. The afferent limb of cellular 
immunity is furnished by the interaction of helper T 
lymphocytes with Class II molecules resulting in 
stimulation of the activity of the killer T cells. 
Endothelial and smooth muscle cells, which might be 
present on cryopreserved arterial allografts, can also 
express Class II antigens. To initiate the immune 
response arterial allografts must contain viable cells 
that have survived the preservation and storage 
processes, must retain, after thawing, the ability to 
express Class II HLA, and finally, must continue to 
bear Class I HLA in order to permit recognition as 
targets by the effector killer T Cells. 
In 1993, we reported that cryopreservation of
arterial allografts did not eradicate smooth muscle 
cells. At the time of surgery we cultured aortic 
allograft-derived smooth muscle cells from unused 
portions of antibiotically treated cryopreserved allog- 
rafts obtained from the major commercial supplier at 
that time. These cells reacted within a human mono- 
clonal antibody that recognises mooth muscle actin 
isoforms, thus identifying them as smooth muscle 
cells. Under basal conditions these cells contained 
messenger ribonucleic acid (mRNA) for Class I HLAs 
detected by northern blotting and expressed Class I 
HLA on their surface as measured by enzyme-linked 
immunoassay (ELISA). Interferon gamma, a product 
of activated T lymphocytes, not only increased expres- 
sion of Class I HLAs by smooth muscle cells, but 
induced Class II human leukocyte mRNA and ele- 
vated surface xpression from 22 to 819 ELISA units. 
Thus, these studies demonstrated that cryopreserved 
aortic allografts contain viable smooth muscle cells 
capable of expressing major histocompatibility anti- 
gen that might render them immunogenic and suscep- 
tible to rejection by the recipient s immune system. 62 
The basis for the second observation is the demon- 
stration by daGama et al. of satisfactory performance 
of arterial allografts in humans under immunosup- 
pression therapy for kidney transplants who subse- 
quently required peripheral arterial revascularisa- 
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tions. 63 Thirteen kidney transplant patients on 
maintenance azothioprine, cyclosporine and predni- 
sone received 16 ABO-compatible arterial allografts. 
Twelve femorofemoral, popliteal and femoroperoneal 
bypass grafts were inserted plus one aortoiliac, one 
iliorenal and two iliofemorals. The arteries were 
retrieved from a cerebral death donor and stored in 
liquid nitrogen vapor. Patients were monitored for up 
to 45 months with a mean of 20 months. Graft 
tolerance was good; there were no signs or symptoms 
of acute graft rejection, and there was no perturbation 
of the immunologic tolerance of the transplanted 
kidney. During the follow-up period two grafts 
occluded, but on the basis of histologic studies, it was 
not possible to relate the occlusion to rejection. 63 
Immunosuppression, however, does not always 
eliminate rejection. When successful, it reduces the 
intensity and duration of the response, but the threat 
is always present. The biologic cost to the immuno- 
suppressed patient and the economic ost to society 
seem out of proportion to the benefit derived, if the 
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Fig. 5. IFN gamma increases the expression of class II HLA on 
homograft-derived SMC. Cultures of aortic homograft-derived SMC 
were incubated for 72 h with or without IFN-alpha, beta, or gamma 
(1000 U/ml). The expression of class I or II MHC antigen on the 
surface of the cultured cells was measured by ELISA. Under control 
conditions cells expressed class I but little or no class II antigen. IFN- 
gamma induced a marked increase inclass I expression a d a more 
modest but statistically significant increase in class I expression 
(p < 0.01). Neither IFN alpha nor beta included a significant 
increase in either class I or class II expression. From: Salomon RN, 
Friedman GB, Callow AD, et aI. Cryopreserved aortic homografts 
contain viable smooth muscle cells capable of expressing trans- 
plantation antigens. J Thorac Cardiovasc Surg 1993; 106: 1173-1180. 
With permission. 
indication is a severely ischaemic limb. A life threat- 
ening situation may improve the cost-benefit ratio. A 
candidate for a peripheral arterial reconstruction who 
is already receiving immunotherapy is a special 
situation. 
Complement 
Morphologic evaluation of allografts harvested as late 
as 5 weeks after implantation has revealed heavy 
infiltration with polymorphonuclear leukocytes 
(PMN). Activated PMNs are known to damage ndo- 
thelial cells in a variety of disease conditions uch as 
immune vasculitis. In 1984, in the course of studying 
the feasibility of endothelial cell seeding of synthetic 
grafts, we noted the occasional appearance of inflam- 
matory cells in the newly formed intima despite an 
apparently satisfactory re-endothelialised graft sur- 
face. Subsequently we demonstrated activation of the 
complement system via both the classical and the 
alternative pathways by what formerly had been 
assumed to be a biologically inert synthetic graft. 64 
This is probably the first evidence that complement 
is a participant in arterial injury healing. It now 
appears that complement occupies a critical role in 
several aspects of the rejection phenomenon. Inhibi- 
tion of the complement cascade may lead to improved 
management of the transplant patient. Ignoring for 
this discussion the hyper-acute rejection which can 
begin within minutes of reperfusion, and chronic 
rejection, such as cardiac transplant atherosclerosis 
and lung transplant obliterative bronchioloitis, acute 
or vascular ejection is generally thought o be due to 
recipient T cell recognition of disparate major and 
minor histocompatibility antigens by either a "direct 
pathway" or an "indirect pathway". "Direct allo- 
recognition" occurs when recipient T cells respond to 
intact allo-MHC molecules on the surface of allogeneic 
cells. "Indirect allo-recognition" occurs when allo- 
MHC molecules are processed by recipient antigen 
presenting cells (APC). 65 Complement receptor 1 
(CR1, CD35) is an example of a natural inhibitor of the 
complement cascade. It has now been shown that a 
recombinant soluble version of complement receptor 1
(sCR1) inhibits both the classical and the alternative 
pathways of the complement cascade in vitro, 66-68 and 
is effective in prolonging organ function i several in 
69- 71 vivo transplant models. - 
An additional potential way of blocking the T 
lymphocytes i  via the recently discovered costimula- 
tory molecule B7-2. 72 Two signals are required for T 
cell activation: 
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Fig. 6. Granulocyte aggregometry acings howing reater PMN aggregation (as measured by large increase in light transmission (&T) for 
plasma exposed to knitted Dacron than to PTFE. Zymosan-activated plasma (AZAP) (4 mg zymosan/1 ml plasma) reflects maximal PMN 
aggregation by known potent activator of complement system. From: Shepard AD, Gelfand JA, Callow AD. Complement activation by 
synthetic vascular prostheses. ] Vasc Surg 1984; 1: 829-838. With permission. 
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Fig. 7. A simplified schema of the complement system depicting the classical and alternative pathways and the possibility of dual activation 
by vascular grafts. From: Shepard AD, Gelfand JA, Callow AD. Complement activation by synthetic vascular prostheses. ]Vasc Surg 1984, 
1: 829-838. With permission. 
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(1) the specific antigen recognised by the T cell 
and 
(2) a costimulatory signal located on the surface of 
the antigen presenting cell activating via receptors CD 
28 and CTLA4 on the cell. Absence of or blocking the 
co-stimulatory signal places the T cell in a state of 
anerg~ in effect, shutting off the T cell specific for a 
given antigen. B7-2 is claimed to be the major player in 
activating T cells. CTLA4-Ig is a specific blocker of B7. 
It thus has the potential to block the T cell rejection 
response to the transplant. 73
Eventually xenotransplantation f arteries and 
veins may become possible. 
Summary 
The problems of unsatisfactory small calibre synthetic 
grafts, re-do vascular operations, and infected vas- 
cular grafts have all contributed to the recently 
renewed interest in the vascular homograft, more 
correctly called, the allograft. The flaws of the allograft 
during the 1950s and 1960s have not been solved 
despite enormous improvements in harvesting, pres- 
ervation and storage. Cryoprotectants have reduced 
the severity and rapidity of onset of allograft failure 
but not eliminated them. Immunosuppression therapy 
has reduced the failure rate somewhat more. Best 
results with allografts are seen in individuals who 
require major arterial restorative surgery and are 
under full immunosuppression because of a pre- 
viously placed organ transplant. Full immunosup- 
pression is probably too high a biologic price to pay to 
relieve an ischaemic limb, but limited suppression via 
inhibition of the complement system may not be. 
Continuing investigation may yield the answer. Until 
then allografts appear to be a useful choice for (1) the 
individual with a real need for revascularisation a d 
who is burdened with a limited life expectancy not 
exceeding the functional life of the allograft, (2) urgent 
replacement of a major vessel damaged by trauma, 
and (3) in situations where immunosuppression is 
contraindicated as in an infected surgical field. The 
allograft probably should not be used (1) simply for 
the relief of intermittent claudication, (2) in the above 
mid-calf location, and (3) in other anatomic locations 
where synthetic grafts perform better. 
Fig. 8. Scanning electron micrograph of surface of knitted Dacron 
graft after 2.5 h of flow in an ex-vivo shunt circuit. Note the adherent 
PMN membrane ruffling and pseudopod formation which indicate 
an activated state. (Original magnification × 13 500). From Shepard 
AD, Geland JA, Callow AD. Complement activation by synthetic 
vascular prostheses. J Vasc Surg 1984; 1: 829-838. With permission. 
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